Cargando…

An exposure‐response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis

The efficacy of ponesimod and teriflunomide for the treatment of relapsing multiple sclerosis (MS) was compared in a randomized phase III trial. This study explores the exposure‐response (E‐R) relationships of efficacy end points (annualized relapse rate [ARR] and combined unique active lesions [CUA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valenzuela, Belén, Olsson Gisleskog, Per, Poggesi, Italo, Sidorenko, Tatiana, Burcklen, Michel, Kracker, Hilke, Pérez‐Ruixo, Juan Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574745/ https://www.ncbi.nlm.nih.gov/pubmed/36047474 http://dx.doi.org/10.1002/psp4.12778

Ejemplares similares

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies
por: Freedman, Mark S., et al.
Publicado: (2022)

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
por: Kappos, Ludwig, et al.
Publicado: (2021)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
por: Ruggieri, Serena, et al.
Publicado: (2022)

Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
Publicado: (2019)

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects
por: Axelsen, Lene Nygaard, et al.
Publicado: (2020)

Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration
por: Olsson Gisleskog, Per O., et al.
Publicado: (2020)

Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome
por: Harrold, John, et al.
Publicado: (2020)

Biocomparison of Three Formulations of the S1P(1) Receptor Modulator Ponesimod in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2015)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Therapeutic Use of a Selective S1P(1) Receptor Modulator Ponesimod in Autoimmune Diabetes
por: You, Sylvaine, et al.
Publicado: (2013)

Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF
por: Harrold, John, et al.
Publicado: (2020)

The Synergistic Anti-Apoptosis Effects of Amniotic Epithelial Stem Cell Conditioned Medium and Ponesimod on the Oligodendrocyte Cells
por: Safaeinejad, Fahimeh, et al.
Publicado: (2021)

Effects of multiple-dose ponesimod, a selective S1P(1) receptor modulator, on lymphocyte subsets in healthy humans
por: Jurcevic, Stipo, et al.
Publicado: (2016)

Ponesimod inhibits astrocyte‐mediated neuroinflammation and protects against cingulum demyelination via S1P(1)‐selective modulation
por: Kihara, Yasuyuki, et al.
Publicado: (2022)

Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment
por: Tervonen, Tommi, et al.
Publicado: (2023)

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019)

The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial
por: Fox, Robert J, et al.
Publicado: (2022)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

The S1P receptor 1 antagonist Ponesimod reduces TLR4-induced neuroinflammation and increases Aβ clearance in 5XFAD mice
por: Zhu, Zhihui, et al.
Publicado: (2023)

Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P(1) Receptor Modulator
por: Rey, Markus, et al.
Publicado: (2013)

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial
por: Laurent, Sarah A., et al.
Publicado: (2023)

Physics, chemistry and biology of functional nanostructures III
por: Sidorenko, Anatolie S
Publicado: (2017)

Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse
por: McKay, Kyla A., et al.
Publicado: (2022)

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
por: Dosne, Anne‐Gaëlle, et al.
Publicado: (2021)

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
por: Yan, Xiaoyu, et al.
Publicado: (2017)

Remissions and Relapses in Insular Sclerosis
Publicado: (1904)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
por: Pantzaris, Marios C, et al.
Publicado: (2022)

Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study
por: Papasouliotis, Orestis, et al.
Publicado: (2022)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

Factors Involved in Relapse of Multiple Sclerosis
por: Kamel, Fatemah Omar
Publicado: (2019)

Osteopontin Is Associated with Multiple Sclerosis Relapses
por: Stampanoni Bassi, Mario, et al.
Publicado: (2023)

The contribution of the acute phase response to the pathogenesis of relapse in chronic-relapsing experimental autoimmune encephalitis models of multiple sclerosis
por: Mardiguian, Silvy, et al.
Publicado: (2017)

Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
por: Havrdova, E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mu4pnlqdhiav1n0ni61jhv7p21